![Thomas Höger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Höger
Director Ejecutivo en Apogenix AG .
Perfil
Thomas Höger is currently the Chief Executive Officer at Apogenix AG since 2009.
Prior to this, he worked as the Head of CNS Research at BASF SE and Knoll AG.
He also worked as an Analyst at DZ Bank AG (Securities).
Cargos activos de Thomas Höger
Empresas | Cargo | Inicio |
---|---|---|
Apogenix AG
![]() Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Director Ejecutivo | 01/11/2005 |
Antiguos cargos conocidos de Thomas Höger.
Empresas | Cargo | Fin |
---|---|---|
DZ Bank AG (Securities) | Analyst-Equity | - |
BASF SE | Corporate Officer/Principal | - |
Knoll AG
![]() Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
BASF SE | Producer Manufacturing |
Empresas privadas | 3 |
---|---|
Apogenix AG
![]() Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Health Technology |
Knoll AG
![]() Knoll AG Pharmaceuticals: MajorHealth Technology Part of BASF SE, Knoll AG develops pharmaceuticals. The company is based in Haren, Germany. | Health Technology |
DZ Bank AG (Securities) | Finance |
- Bolsa de valores
- Insiders
- Thomas Höger